The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

By Jérôme Galon, H. Angell, D. Bedognetti, F. Marincola. Immunity, 2013

811 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/2a2d3963d2d03e09a8415d246e8d47d58113df9b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Xue Han
2. Daniel S. Chen
3. I. Mellman
4. S. Demaria
5. K. Odunsi
6. Lieping Chen
7. W. Zou
8. D. Pardoll

In Oncology

1. Xue Han
2. Daniel S. Chen
3. J. Reis-Filho
4. A. Richardson
5. David L. Rimm
6. S. Demaria
7. J. Brock
8. I. Mellman

In Psychiatry and Mental health

1. Xue Han
2. Lieping Chen

Citations in the corpus

• Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images (2018, background): “Although studies in humans have shown that chronic inflammation can promote tumorigenesis (Trinchieri, 2012), the host immune system is equally capable of controlling tumor growth through the activation of adaptive and innate immune mechanisms (Galon et al., 2013).”
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015, positive): “Immune infiltration is a reliable indicator of tumor immunogenicity, and it has been shown that the presence of gene signatures for CD8+ T cells and Th1 cells are associated with a better prognosis for several types of cancers, including colorectal and lung cancers, whereas Tregs, MDSCs, Th2 cells, ”
• Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 (2018, neutral): “Considering that IFN-g and interleukin 12 (IL-12) are key immune players in tissue-specific destruction (Galon et al., 2013; Nastala et al., 1994), we used intravital imaging to track these factors within tumors after aPD-1 treatment.”
• Oncology meets immunology: the cancer-immunity cycle. (2013, background): “…articles contained in this issue each address key aspects of how the immune response can control or be manipulated to enhance anticancer immunity (Galon et al., 2013; Kalos and June, 2013; Motz and Coukos, 2013; Palucka and Banchereau, 2013; van den Boorn and Hartmann, 2013; Zitvogel et al.,…”